IL2 and metastatic melanoma: Combination of high‐dose IL‐2 with PD‐1/PD‐L1 blockade therapy displays an objective response rate (ORR) of 22.5% and 24% for metastatic melanoma and metastatic renal cell carcinoma (RCC), respectively.37